Aurora Cannabis reported a narrower net loss of C$17.2 million for its fiscal fourth quarter, compared to a C$20.3 million loss the previous year, driven by strong growth in its global medical-cannabis business. Net revenue rose to C$90.5 million, exceeding analyst expectations of C$88.8 million, with a 48% increase in medical cannabis revenue and a 32% rise in its plant-propagation unit. The consumer-cannabis segment experienced a 20% decline, as the company focuses on higher-margin medical products.
Aurora Cannabis (ACB) reported a significant improvement in its fiscal fourth-quarter financial performance, with its net loss narrowing to C$17.2 million from C$20.3 million year-over-year. The company achieved net revenue of C$90.5 million, an increase from C$67.4 million in the prior-year period and notably exceeding analyst consensus estimates of C$88.8 million. This revenue growth was primarily propelled by a robust 48% surge in its global medical-cannabis business and a 32% increase in its plant-propagation unit. Adjusted EBITDA also demonstrated substantial growth, reaching C$16.7 million, a significant rise from C$2.32 million and surpassing the C$15.2 million forecast by analysts. This improved profitability reflects Aurora's strategic prioritization of its higher-margin global medical-cannabis operations, a focus that has led to a deliberate 20% contraction in its consumer-cannabis segment, which recorded revenues of C$8.2 million.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
